The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...

AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations, with ...